Human medicines European public assessment report (EPAR): Plerixafor Accord, plerixafor, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Date of authorisation: 29/07/1999, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zonegran, zonisamide, Date of authorisation: 10/03/2005, Revision: 38, Status: Authorised

Concept paper on revision of: Guideline on similar biological medicinal products, CHMP/437/04 Rev.1

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Date of authorisation: 20/09/2017, Revision: 39, Status: Authorised

Agenda - PDCO agenda of the 21-24 July 2026 meeting

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 9, Status: Authorised